Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Virgin Galactic Holdings Inc SPCE

Virgin Galactic Holdings, Inc. is an aerospace and space travel company, which offers access to space for private individuals, researchers, and government agencies. The Company’s operations include design and development, manufacturing, ground and flight testing, and post-flight maintenance of its spaceflight system vehicles. The Company has developed a portfolio of proprietary technologies that are embodied in the specialized vehicles that it has created to enable commercial spaceflight. These technologies include carrier aircraft, the mothership; its spaceships; its hybrid rocket motor, and its safety systems. Its Carrier Aircraft-The Mothership is a twin-fuselage, custom-built aircraft designed to carry spaceships up to an altitude of approximately 45,000 feet, where the spaceship is released for its flight into space. Its Virgin Galactic spaceships are reusable with the capacity to carry pilots and private astronauts, research experiments and researchers.


NYSE:SPCE - Post by User

Post by Shierleyon Apr 19, 2022 11:46pm
199 Views
Post# 34615408

FSD Pharma Inc: Lucid MS Video

FSD Pharma Inc: Lucid MS Video


FSD Pharma is delighted to announce pre-clinical findings indicating the efficacy of Lucid-MS, its flagship medication candidate, in treating Multiple Sclerosis. Lucid-MS's therapeutic potential is an industry first, and we'd like to provide visual evidence of functional recovery in pre-clinical individuals in this video!

<< Previous
Bullboard Posts
Next >>